psoriasis Archives - Drugs in Context

Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptoms

Annunziata Dattola, Nicoletta Bernardini, Jasmine Anedda, Laura Atzori, Claudio Bonifati, Pier Luigi Bruni, Domenico Giordano, Dario Graceffa, Elisa Molinelli, Gaia Moretta, Cristina Mugheddu, Annamaria Offidani, Gianluca Pagnanelli, Sabatino Pallotta, Manuela Papini, Severino Persechino, Antonio Giovanni Richetta, Ersilia Tolino, Federica Trovato, Giovanni Pellacani, Concetta Potenza

Article Type

Original Research

Published

08 Sep 2025

This article aims to evaluate the effect of IL-23 inhibitors on clinical outcomes and progression of PsA in patients with moderate-to-severe psoriasis and early musculoskeletal involvement.

Real-world experience with brodalumab in a Portuguese cohort of patients with moderate-to-severe psoriasis

Tiago Torres, Pedro Mendes-Bastos, Joana Antunes, Maria João Cruz, Fernando Mota, Paulo Ferreira

Article Type

Original Research

Published

13 Mar 2025

This study aimed to evaluate the real-world efficacy and safety of brodalumab treatment in a Portuguese population.

Fixed-dose combination of calcipotriene/betamethasone dipropionate foam for the management of mild-to-moderate psoriasis in daily clinical practice: a collection of clinical experiences

Anna Campanati, Maria Esposito, Giacomo Caldarola, Sara Cacciapuoti, Gabriella Fabbrocini

Article Type

Case Series

Published

09 Oct 2024

This article reports on a discussion between a group of experts regarding the value of the Cal/BD foam as a topical treatment for mild-to-moderate psoriasis in combination with systemic treatments. Experiences support effectiveness of the Cal/BD foam in daily clinical practice, with an improvement in patient quality of life.

Rapid Efficacy of riSankizumab in pretibial psoriasis invOLVEment: RESOLVE

Nicoletta Bernardini, Nevena Skroza, Laura Atzori, Cristina Mugheddu, Matteo Megna, Sara Cacciapuoti, Michela Ortoncelli, Maria A Montesu, Antonio Carpentieri, Martino Carriero, Maria G Atzori, Gianmario Addis, Riccardo Balestri, Giulia Rech, Pierluigi Bruni, Manuela Papini, Concetta Potenza

Article Type

Original Research

Published

05 Sep 2024

This multicentre study focuses on psoriasis affecting sensitive areas, its impact on quality of life and the therapeutic response to risankizumab.

New and emerging oral therapies for psoriasis

Orhan Yilmaz, João Pedro Pinto, Tiago Torres

Article Type

Review

Published

01 Aug 2024

This narrative review synthesizes the emerging oral therapeutic agents for psoriasis, focusing on their mechanisms of action, stages of development and clinical trial results.